We found that low FGD3 expressing patients had higher incidence of lymph node metastases as compared with high FGD3 expressing ones, (61.9% versus 41.0%), but the difference was not significant (p = 0.12). This evidence concerns the gene FGD3 and metastatic malignant neoplasm in the lymph nodes.